The FDA’s top vaccine regulator said Monday that the U.S. maintains a stockpile of vaccines targeting avian flu.
“There are actually vaccines licensed in the United States for H5N1, and there are stockpiles where we believe that, if we needed to, they would be reasonably good matches,” Dr. Peter Marks said at the World Vaccine Congress in Washington.
Whether the federal government would activate more production of those countermeasures depends on how the situation unfolds, Marks indicated."Just because of being on edge from Covid, there are a lot of people looking at what’s going on here, and there’s probably a pretty low threshold to pull the trigger here,” he said. “This is one case we’re a little luckier because it’s a pathogen that we know. We know what this is and what we have in the freezer, so to speak. We have a little bit of a leg up on at least getting started.”
But Dr. Luciana Borio, a former FDA official, questioned the vaccines’ potency. The shots’ two-dose regimen, which the FDA approved in 2007, produced antibody levels expected to reduce the risk of getting avian flu by 45 percent.
“I’m not as confident as Dr. Marks,” she said after his remarks.
There is also concern about potential cow-to-cow spread in Idaho. State veterinarian Scott Leibsle told POLITICO that cows from an Idaho dairy tested positive for avian influenza a few weeks after a shipment of Texas cattle arrived in early March from a facility with avian influenza cases.
“The coincidence of timing is just too coincidental to say well, the shipment of cattle came up from an affected facility in Texas and then two weeks later we saw it in some other cattle,” Leibsle said. “That just doesn’t make any sense.”
The FDA said it is not aware of milk or food products from symptomatic cows entering interstate commerce. The three government agencies said there is “no concern about the safety of the commercial milk supply” because of pasteurization — which heats milk to a temperature that would kill the virus.